Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-01-31

Study Completion Date

2008-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to measure the hair growth response to topical NEOSH101 when applied twice daily to the balding scalp for 16 weeks. One hundred eighty men with Norwood/Hamilton grades III-IV with thinning in the top and center of the scalp will participate. Three equally sized treatment groups (60 men each) will receive either topical NEOSH101 2.0%, minoxidil 5%, or placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss

NCT00471510

Androgenetic Alopecia

UNKNOWN PHASE2

A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss

NCT00151515

Androgenetic Alopecia

COMPLETED PHASE3

Microarray Analysis of Scalp Biopsies After Minoxidil Treatment

NCT01309191

Androgenetic Alopecia

COMPLETED NA

Minoxidil Response Testing in Males With Androgenetic Alopecia

NCT02198261

Androgenetic Alopecia

COMPLETED

Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

NCT02676310

Alopecia Alopecia, Androgenetic Baldness

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Androgenetic Alopecia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

tetrapeptide aldehyde proteasome inhibitor (NEOSH101)

Intervention Type DRUG

Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days

2

Group Type ACTIVE_COMPARATOR

tetrapeptide aldehyde proteasome inhibitor (NEOSH101)

Intervention Type DRUG

Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days

3

Group Type PLACEBO_COMPARATOR

tetrapeptide aldehyde proteasome inhibitor (NEOSH101)

Intervention Type DRUG

Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tetrapeptide aldehyde proteasome inhibitor (NEOSH101)

Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Caucasian men, in general good health, aged 18-49 years
* Norwood/Hamilton grades III-IV, with thinning hair in the vertex area

Exclusion Criteria

* concomitant dermatologic or medical condition(s) which may interfere with the investigator's ability to evaluate the subject's response to the study drug
* treatment with a systemic or locally acting medication which may interfere with the study objectives, such as minoxidil treatment in the 6 months prior to study start, finasteride treatment in the 12 months prior to study start, or treatment with other investigational hair growth products in the 6 months prior to study start

Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes